Our Pipeline
We never lose sight of why our work matters – the potential to impact the lives of patients is important to everyone at Sana. We are advancing a number of innovative drug candidates with the goal of disrupting the possible for patients across a diverse set of diseases.
Pipeline
SC291 (CD19)
T cells
Oncology
• Non-Hodgkin lymphoma (NHL)
• Acute lymphoblastic leukemia (ALL)
• Chronic lymphocytic leukemia (CLL)
Pre Clinical
SC262 (CD22)
T cells
Oncology
• Non-Hodgkin lymphoma (NHL)
• Acute lymphoblastic leukemia (ALL)
• Chronic lymphocytic leukemia (CLL)
Pre Clinical
SC255 (BCMA)
T cells
Oncology
Multiple myeloma
Pre Clinical
SC451
Islet cells
Diabetes
Type 1 diabetes
Pre Clinical
SC379
Glial progenitor cells
Central nervous system (CNS)
• Huntington’s disease
• Pelizaeus-Merzbacher disease
• Secondary progressive multiple sclerosis
Pre Clinical
SG295 (CD8/CD19)
T cells
Oncology
• Non-Hodgkin lymphoma (NHL)
• Acute lymphoblastic leukemia (ALL)
• Chronic lymphocytic leukemia (CLL)
Pre Clinical
SG239 (CD8/BCMA)
T cells
Oncology
Multiple myeloma
Pre Clinical
SG242 (CD4/CD19)
T cells
Oncology
• Non-Hodgkin lymphoma (NHL)
• Acute lymphoblastic leukemia (ALL)
• Chronic lymphocytic leukemia (CLL)
Pre Clinical
SG221 (CD4/BCMA)
T cells
Oncology
Multiple myeloma
Pre Clinical
SG233 (CD8/CD22)
T cells
Oncology
• Non-Hodgkin lymphoma (NHL)
• Acute lymphoblastic leukemia (ALL)
• Chronic lymphocytic leukemia (CLL)
Pre Clinical
SG418
Hematopoietic stem cells
Hemoglobinopathies
• Sickle cell disease
• Beta-thalassemia
Pre Clinical
We use cookies to improve your experience on our website. By continuing to use this website, you agree to the use of cookies. To learn more about how we use cookies, please see our Privacy Policy.
Your access to, and use of, our website is subject to our Terms of Use and all applicable laws and regulations. By accessing and using our website, you accept these Terms of Use. To learn more about the Terms of Use, please visit Terms of Use.
ⓒ 2020-2023 Sana Biotechnology. All rights reserved.
